WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562785
CAS#: 35998-29-9
Description: HBED is an iron chelator used for treatment of chronic iron overload and acute iron poisoning.
MedKoo Cat#: 562785
Name: HBED
CAS#: 35998-29-9
Chemical Formula: C20H24N2O6
Exact Mass: 388.16
Molecular Weight: 388.42
Elemental Analysis: C, 61.85; H, 6.23; N, 7.21; O, 24.71
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: HBED; CHEL II; CHEL-II; CHELII;
IUPAC/Chemical Name: 2,2'-(ethane-1,2-diylbis((2-hydroxybenzyl)azanediyl))diacetic acid
InChi Key: GRUVVLWKPGIYEG-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H24N2O6/c23-17-7-3-1-5-15(17)11-21(13-19(25)26)9-10-22(14-20(27)28)12-16-6-2-4-8-18(16)24/h1-8,23-24H,9-14H2,(H,25,26)(H,27,28)
SMILES Code: OC1=CC=CC=C1CN(CCN(CC(O)=O)CC2=CC=CC=C2O)CC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 388.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Cuccurullo V, Di Stasio GD, Mansi L. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers. World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi: 10.4103/wjnm.WJNM_54_17. Review. PubMed PMID: 29719480; PubMed Central PMCID: PMC5905261.
2: Bailey J, Piert M. Performance of (68)Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence. Curr Urol Rep. 2017 Sep 9;18(11):84. doi: 10.1007/s11934-017-0736-1. Review. PubMed PMID: 28889366.
3: von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2016 Nov 15. pii: S2405-4569(16)30160-2. doi: 10.1016/j.euf.2016.11.002. [Epub ahead of print] Review. PubMed PMID: 28753806.
4: Knorr K, Eiber M, Maurer T, Wester HJ, Scheidhauer K. [PET-CT and PET-MRI of the prostate : From (18)F-FDG to (68)Ga-PSMA]. Radiologe. 2017 Aug;57(8):631-636. doi: 10.1007/s00117-017-0276-1. Review. German. PubMed PMID: 28688023.
5: Fitzpatrick C, Lynch O, Marignol L. (68)Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease. Anticancer Res. 2017 Jun;37(6):2753-2760. Review. PubMed PMID: 28551611.
6: Michaud L, Touijer KA. Molecular imaging for prostate cancer: Performance analysis of (68)Ga-PSMA PET/CT versus choline PET/CT. Actas Urol Esp. 2017 Jun;41(5):292-299. doi: 10.1016/j.acuro.2016.09.015. Epub 2016 Nov 30. Review. English, Spanish. PubMed PMID: 27912910.
7: Rauscher I, Eiber M, Jilg CA, Gschwend JE, Maurer T. [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects]. Urologe A. 2017 Jan;56(1):18-23. doi: 10.1007/s00120-016-0275-2. Review. German. PubMed PMID: 27885455.
8: Schreiter V, Reimann C, Geisel D, Schreiter NF. Nuclear Medicine Imaging of Prostate Cancer. Rofo. 2016 Nov;188(11):1037-1044. Epub 2016 Jun 14. Review. PubMed PMID: 27299668.
9: Incerti E, Mapelli P, Gianolli L, Picchio M. PET imaging for lymph node dissection in prostate cancer. World J Urol. 2017 Apr;35(4):507-515. doi: 10.1007/s00345-016-1954-8. Epub 2016 Oct 17. Review. PubMed PMID: 27752756.
10: Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004. Review. PubMed PMID: 27553466.
11: Düwel C, Eiber M, Maurer T. [Will 68Ga-PSMA PET become the New Imaging Standard for Prostate Cancer?]. Aktuelle Urol. 2016 Sep;47(5):378-82. doi: 10.1055/s-0042-110982. Epub 2016 Jul 28. Review. German. PubMed PMID: 27467591.
12: Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Review. PubMed PMID: 27363387.
13: Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016 Jun 8;16(1):14. doi: 10.1186/s40644-016-0072-6. Review. PubMed PMID: 27277843; PubMed Central PMCID: PMC4898465.
14: Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016 Apr;13(4):226-35. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23. Review. PubMed PMID: 26902337.
15: Hellwig D, Moosbauer J, Eilles C. [Ga-68-PSMA PET/CT for prostate cancer]. Aktuelle Urol. 2014 Nov;45(6):457-63. doi: 10.1055/s-0034-1395529. Epub 2014 Dec 17. Review. German. PubMed PMID: 25518963.
16: Cho SY, Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med. 2014 Mar;44(2):93-109. doi: 10.1053/j.semnuclmed.2013.10.008. Review. PubMed PMID: 24484747; PubMed Central PMCID: PMC3912464.
17: Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13(8):951-62. Review. PubMed PMID: 23590171; PubMed Central PMCID: PMC4067736.
18: Leung K. (68)Ga-N,N’-bis[2-Hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N’-diacetic acid-polyethylene glycol-single-chain Cys-tagged vascular endothelial growth factor-121. 2010 Dec 18 [updated 2011 Feb 17]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK52786/ PubMed PMID: 21348057.
19: Leung K. (68)Ga-Labeled anti-EpCAM diabody against epithelial cell adhesion molecule. 2010 Aug 6 [updated 2010 Nov 19]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK49245/ PubMed PMID: 21089232.
20: Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004:14-34. Review. PubMed PMID: 15561674.
